Nitroglycerin tablet patient counseling information

Revision as of 17:55, 31 January 2014 by Pratik Bahekar (talk | contribs) (Created page with "__NOTOC__ {{Nitroglycerin}} {{CMG}}; {{AE}} {{PB}} ==Patient Counseling Information== <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NITROSTAT (...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Nitroglycerin
NITROSTAT® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
MINITRAN® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]

Patient Counseling Information

[1]


References

  1. ↑ "NITROSTAT (NITROGLYCERIN) TABLET [PARKE-DAVIS DIV OF PFIZER INC]". Retrieved 31 January 2014.
Retrieved from "https://www.wikidoc.org/index.php?title=Nitroglycerin_tablet_patient_counseling_information&oldid=936685"